Overview

XOMA is currently engaged in multiple active development projects across several therapeutic areas including cardio-metabolic, inflammatory, autoimmune and infectious disease, and cancer. We develop both proprietary and partnered products using our extensive suite of antibody technologies. We are growing and advancing a rich pipeline of antibody therapeutics, and we have contributed to the development of products that are currently marketed by Genentech and UCB.

Our pipeline of drug candidates includes XOMA 052, a paradigm-changing antibody for treatment of patients with Type 2 diabetes. We have evaluated XOMA 052 in two clinical studies inType 2 diabetes patients for its potential to target key inflammatory pathways that contribute to the death and impairment of insulin-producing cells. We plan to advance XOMA 052 into additional clinical studies for the treatment of other inflammatory conditions, and are evaluating its potential in cardiovascular disease.

In addition to developing exciting proprietary antibody product candidates, our research teams have contributed to the development of approved antibody therapies. We have also contributed significantly to the development of HCD122, a monoclonal antibody to CD40 partnered with Novartis, and numerous other discovery and development projects.